PU-AD

DRUG4 trials

Sponsors

Samus Therapeutics, Inc.

Conditions

Alzheimer DiseaseAlzheimer's DiseaseAmyotrophic Lateral Sclerosis (ALS)LymphomaMyelomaSolid Malignancy

Early Phase 1

PET Imaging of Subjects Using 124I-PU-AD

TerminatedNCT03371420

Samus Therapeutics, Inc.Alzheimer Disease, Lymphoma, Myeloma +1

Start: 2016-04-30End: 2019-06-10Updated: 2023-04-18

Phase 1

A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects

TerminatedNCT03935568

Samus Therapeutics, Inc.Alzheimer's Disease

Start: 2019-06-24End: 2019-12-23Updated: 2023-04-18

Phase 2

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

TerminatedNCT04311515

Samus Therapeutics, Inc.Alzheimer Disease

Start: 2020-06-30End: 2022-11-15Updated: 2022-11-17

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis

WithdrawnNCT04505358

Samus Therapeutics, Inc.Amyotrophic Lateral Sclerosis (ALS)

Start: 2023-01-31End: 2025-01-31Updated: 2022-11-17

Related Papers

Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system

Nature Communications2021-08-0332 citations